Aptar and Sonmol develop digital platform for respiratory-related therapies

Collaboration includes strategic investment by Aptar Pharma

708
Aptar
Photo - Aptar

AptarGroup, a global leader in consumer dispensing, active packaging and drug delivery solutions and services, and Sonmol, a leading Chinese digital respiratory therapeutics company, have announced a collaboration for developing a digital therapies and services platform targeting respiratory and other diseases. This collaboration will initially focus on bringing together connected drug delivery devices and the digital platform for asthma and chronic obstructive pulmonary disease (COPD). Aptar Pharma and Sonmol will work together on expanding Sonmol’s platform services to enable remote patient monitoring, improve patient and physician interactions, increase patient engagement and adherence, and improve health outcomes. The partnership will work with pharmaceutical and healthcare partners to accelerate the development, manufacturing, commercialization and supply of digital respiratory medicines, diagnostics and patient support services in China and other Asian markets for marketed and pipeline drugs. The collaboration significantly bolsters Aptar’s digital health offerings in Asia by combining Aptar Pharma’s expertise in connected drug delivery device development, innovation and quality manufacturing together with Sonmol’s connected devices, data platform and patient management services. Stephan Tanda, president and chief executive…

Choose your subscription to read more

Trial

0 /mo
Not sure which package to choose? Try full access
  • ₹ 0 for 4 weeks*

PSA Plan 1

1500 /year
Access to the website, weekly eMail newsletter and monthly eMag
  • ₹1,500.00 for 1 year*

PSA Plan 2

2000 /Year
Print Copy, access to the website, weekly eMail newsletter and monthly eMag
  • ₹2000 for Year*

PSA Plan 3

3600 /2Year
Print Copy, access to the website, weekly eMail newsletter and monthly eMag
  • ₹3,600.00 for 2 year*